ClinicalTrials.gg
RecruitingNCT06082063Steno1Updated Jan 10, 2025

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

A Phase 3 interventional study of Aspirin tablet and Semaglutide in Cardiovascular Diseases, Heart Failure and Type 1 Diabetes, sponsored by Steno Diabetes Center Copenhagen. Recruiting at 2 sites in Denmark. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-01-10.

Primary conditionHeart FailureRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Failure
Why
  1. The study's listed conditions name Heart Failure, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Steno Diabetes Center Copenhagen · Phase 3, Interventional, and Treatment

How we know · 10 judgments

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.

Planned enrollment
34th of 187
2,000 · median 197
Started
2024
with 16 others
Phase 3
38 of 242
7 open now
Primary completion
2029-07
later than 45 of 59 live
Registered
196th of 242
by date

Among the 242 studies in Heart Failure with a site in Denmark, this one is the 34th largest by planned enrollment of the 187 interventional ones that give a count, is one of 17 that started in 2024, is one of 38 in phase 3, reaches primary completion later than 45 of the 59 other live ones, and was the 196th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 242 studies in Heart Failure with a site in Denmark, or all of them as a file.
02

Study summary

A prospective, randomised, open-labelled, multi-center study. The aim of the Steno 1 study is to test multifactorial intervention in individuals with type 1 diabetes at high risk of CVD with ambitious treatment targets. We will include 2000 participants. Follow-up is 5 years.

Read the detailed description

Background: Individuals with type 1 diabetes (T1D) are at high risk for cardiovascular disease (CVD). Even with optimal glycemic control, the risk is doubled compared to healthy individuals. Treatment of type 2 diabetes (T2D) is based on multifactorial intervention (MFI). The development of new drug classes has had profound impact on treatment guidelines through a documented reduction in mortality and morbidity in individuals with T2D. MFI acknowledges the need for control and interventions directed towards several risk factors for CVD, and not focus merely on glucose levels. A fundamental change in risk management with a strong focus on MFIs to lower CVD risk in individuals with T1D and comorbidity of CVD, CKD, HF or obesity, has the potential to improve morbidity and survival in T1D.

Objective: The aim of the Steno 1 study is to test MFI in individuals with T1D at high risk of CVD with ambitious treatment targets. We hypothesize, that the MFI reduces major adverse cardiovascular endpoints (MACE) hospitalization for heart failure (HHF), kidney failure and mortality.

Design: This study uses a PROBE design (prospective, cluster-randomized, open, blinded endpoint evaluation), as it will not be possible to mask the MFI. The study is a superiority trial.

Patient population: High-risk individuals with T1D of >10 years duration (>40 years of age with presence of either CKD, CVD, HF, obesity or a >10% 5-year CVD risk determined by the Steno T1 Risk Engine). Participants are recruited from Steno Diabetes Centres or partner clinics.

Randomization: There will be formed three clusters (large patient pool, intermediate- and small). Within each cluster, participating centers will be randomised to either group A or group B. Group A will receive current guideline-recommended standard of care and group B will receive the multifactorial risk based intensive therapy. Participants are allocated to centers based on geography and not based on phenotype.

Intervention: For the intensively treated group, the MFI will be determined by the risk profile and risk markers of each individual and the participants will be allocated to Semaglutide, sotagliflozin, finerenone, ezetimibe and/ or PCSK9-inhibitors. The intervention will also comprise more ambitious treatment targets for blood pressure and lipid levels. In addition, all participants will take aspirin 75 mg OD.

Endpoints: The primary endpoint is to determine whether MFI is superior to standard care with respect to MACE+HHF (composite of time to first non-fatal myocardial infarction, first non-fatal stroke, cardiovascular death or first hospitalization for heart failure). Secondary endpoints are to determine whether MFI is superior to standard care with respect to all-cause mortality, a composite endpoint of renal function (end-stage kidney disease (ESKD) (dialysis, renal death, transplantation) or >50% sustained decline in eGFR) compared to standard of care and to determine whether MFI including the use of SGLT2i and GLP1RA leads to an increased frequency of diabetic ketoacidosis compared to standard of care.

03

Conditions studied

  • Cardiovascular Diseases
  • Heart Failure
  • Type 1 Diabetes
  • Kidney Failure
04

In context

Heart Failure Reclassified

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Steno Diabetes Center Copenhagen is the lead sponsor of 114 studies on the registry; 22 are open to participants now.

Compared within Heart Failure, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Given written
  2. Male or female patients ≥40 years old with type 1 diabetes (diagnosis before age 30 with insulin from onset or if diagnosis after 30 years of age insulin from onset and DKA or positive autoantibodies ( in accordance with local guidelines)) during >10 years.
  3. Presence of chronic kidney disease (UACR >30 mg/g or \< 60 ml/min/1.73 m2) OR history of ischemic heart disease (previous myocardial infarction, stroke or angina) OR history of heart failure OR obesity grade 2 and 3 (>35 kg/m2) OR 10-year CVD risk >10% according to Steno Type 1 Risk Engine.
  4. Fertile females must use highly efficient chemical, hormonal and mechanical during the whole study and at least 2 months after cessation of study drug. The following contraceptive methods are approved: IUD or hormonal contraception that inhibits ovulation, i.e. pills, implantations, transdermal patches, vaginal ring or depot injection. Alternatively, be in menopause (i.e. must not have had regular menstrual bleeding for at least one year), have undergone bilateral oophorectomy or have been surgically sterilized or hysterectomised at least 12 months prior to screening. Fertile participants will be pregnancy tested every six months with urine HCG.
  5. Ability to communicate with the investigator and understand informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Type 2 diabetes, MODY, secondary diabetes.
  2. History of pancreatitis.
  3. \< 18.5 kg/m2
  4. Females of who are pregnant, breast-feeding, intend to become pregnant or are not using adequate methods.
  5. Known or suspected abuse of alcohol or recreational drugs.
  6. Participant in another intervention study.
  7. CKD stage 5.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    Multifactorial intervention group

    The multifactorial intervention will be determined by the risk profile and risk markers of each individual and the participants will be allocated to Semaglutide, sotagliflozin or finerenone. The intervention will also comprise more ambitious treatment targets for blood pressure and lipid levels. In addition, all participants will take aspirin 75 mg OD.

    Drug: Aspirin tablet · Drug: Semaglutide · Drug: Sotagliflozin · Drug: Finerenone

  • No intervention
    Standard intervention group

    During the whole study period the standard intervention shall be done according to current Danish and international (ADA/EASD) guidelines. This will address similar risk factors as in the intensive group, but to a less ambitious treatment target for blood pressure and lipid lowering and will not include the use of SGTL2i, finerenone or GLP-1RA, unless these drug classes become recommended in future versions of guidelines.

Interventions

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.

  • GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c \>53 mmol/mol or BMI\>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.

  • SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR \>30 mg/g and eGFR \< 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (\<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.

  • Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (\>30 mg/g) despite RAS blockade.

07

What researchers measure

Primary outcomes

  1. MACE + HHF

    Calculate the incidence of cardiovascular events (MACE+HF) to determine whether a multifactorial intervention is superior to standard care with respect to MACE+HHF (composite of time to first non-fatal myocardial infarction, first non-fatal stroke, cardiovascular death or first hospitalization for heart failure).

    Time frame: 5 years

Secondary outcomes

  1. All-cause mortality

    Calculate the incidence of all-cause mortality to determine whether a multifactorial intervention is superior to standard care with respect to all-cause mortality.

    Time frame: 5 years

  2. Renal function

    Calculate the incidence of ESKD to determine whether a multifactorial intervention is superior to standard care with respect to renal function (end-stage kidney disease (ESKD) (dialysis, renal death, transplantation) or \>50% sustained decline in eGFR) compared to standard of care.

    Time frame: 5 years

  3. Diabetic ketoacidosis, safety

    Calculate the incidence of DKA to determine whether a multifactorial intervention including the use of SGLT2i and GLP-1RA leads to a change in the frequency of diabetic ketoacidosis compared to standard care.

    Time frame: 5 years

Other outcomes

  1. Indivudual components of the primary endpoint

    To determine whether a multifactorial intervention is superior to standard care with respect to the individual components of the primary endpoint.

    Time frame: 5 years

  2. Lower extremity amputations

    Calculate the incidence of lower extremity amputations to determine whether a multifactorial intervention is superior to standard of care in reducing the total number of lower extremity amputations.

    Time frame: 5 years

  3. Progression of retinopathy

    Calculate the incidence of progression to retinopathy to determine whether a multifactorial intervention is superior to standard of care in reducing progression of retinopathy.

    Time frame: 5 years

  4. Reduction in kidney function

    Calculate the reduction in eGFR (ml/min/1.73m2) to determine whether a multifactorial intervention is superior to standard care with respect to sustained reduction in kidney function (\>30% decline in eGFR as well as \>40% decline in eGFR).

    Time frame: 5 years

  5. EQ5D questionnaire

    To determine whether a multifactorial intervention is superior to standard care with respect to quality of life as measured with the EQ5D questionnaire.

    Time frame: 5 years

  6. 5- and 10-year cardiovascular risk as assessed using the Steno T1 Risk Engine

    To calculate the 5- and 10 year risk of cardiovascular disease at baseline and after 3 and 5 years by the use of the Steno T1 Risk engine to determine whether a multifactorial intervention reduces estimated 5- and 10-year cardiovascular risk compared to standard of care.

    Time frame: 5 years

  7. Urinary albumin to creatinine ratio (UACR)

    Measurement of urinary albumin to creatinine raio (UACR) mg/g at baseline and after 3 and 5 years to determine whether a multifactorial intervention reduces urinary albumin to creatinine ratio (UACR) compared to standard of care.

    Time frame: 5 years

  8. Decline in eGFR

    Measure eGFR (ml/min/1.72 m2) at baseline and after 3 and 5 years to determine whether a multifactorial intervention reduces decline in eGFR compared to standard of care.

    Time frame: 5 years

  9. HbA1c

    Measure HbA1c (mmol/mol) at baseline and after 3 and 5 years to determine whether a multifactorial intervention reduces HbA1c levels compared to standard of care.

    Time frame: 5 years

  10. LDL cholesteerol

    Measure LDL-cholesterol (mmol/L) at baseline and after 3 and 5 years to determine whether a multifactorial intervention reduces LDL cholesterol levels compared to standard of care.

    Time frame: 5 years

  11. BMI

    Measure height (cm) and weight (kg) at baseline and after 3 and 5 years to calculate BMI (kg/m2) to determine whether a multifactorial intervention reduces BMI compared to standard of care.

    Time frame: 5 years

  12. Biothesiometry

    Measure biothesiometry (V) at baseline and efter 3 and years to determine whether a multifactorial intervention reduces biothesiometry score compared to standard of care.

    Time frame: 5 years

  13. Diabetic ketoacidosis (DKA)

    Calculate events of DKA at baeline and after 3 and 5 years to calculate the incidence of DKA to compare incidence of diabetic ketoacidosis between the groups.

    Time frame: 5 years

  14. Long term risk of CVD events

    Calculate the incidence of cardiovascular events (MACE+HHF) at 5 and 10 years to compare in both groups

    Time frame: 10 years

  15. Survival

    Calculate mortality rates after 5 and 10 years to compare overall survival between the groups

    Time frame: 10 years

  16. Long term risk of ESKD

    Calculate rates of ESKD after 5 and 10 years to compare number of individuals developing ESKD in both groups.

    Time frame: 10 years

  17. Long term risk of lower extremity amputations

    Calculate numbers of lower extremity amputations after 5 and 10 years to compare between the groups.

    Time frame: 10 years

  18. Long term risk of DKA

    Calculate the incidence of DKA after 5 and 10 years to compare between the groups.

    Time frame: 10 years

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2029, 60 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 60 months is above that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
Oct 13, 2023
StartActual
Jul 1, 2024
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2029
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06082063
Collaborators
Aarhus University Hospital, Steno Diabetes Center Nordjylland, Steno Diabetes Center Odense, Slagelse Hospital, Nykøbing Falster County Hospital, Zealand University Hospital, Hillerod Hospital, Denmark, Rigshospitalet, Denmark, Hvidovre University Hospital, Regionshospitalet Viborg, Skive, Randers Regional Hospital, Herning Hospital, Esbjerg Hospital - University Hospital of Southern Denmark, Regionshospitalet Silkeborg, Bispebjerg Hospital, Regionshospitalet Horsens
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Jul 1, 2024
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Jan 10, 2025

Study contacts

Frederik Persson, MD, DMSc
Contact
frederik.persson@regionh.dk
+4521623779
Elisabeth Stougaard, MD
Contact
elisabeth.buur.stougaard@regionh.dk
+4522436292
Peter Rossing, MD, DMSc, Proffessor
principal investigator · Steno Diabetes Center Copenhagen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Semaglutide · Sotagliflozin · Finerenone

Start the discussion